AAAAAA

   
Results: 1-14 |
Results: 14
PHASE-I TRIAL OF PACLITAXEL AND GEMCITABINE ADMINISTERED EVERY 2 WEEKS IN PATIENTS WITH REFRACTORY SOLID TUMORS
Authors: ROTHENBERG ML SHARMA A WEISS GR VILLALONACALERO MA ECKARDT JR AYLESWORTH C KRAYNAK MA RINALDI DA RODRIGUEZ GI BURRIS HA ECKHARDT SG STEPHENS CD FORRAL K NICOL SJ VONHOFF DD
Citation: Ml. Rothenberg et al., PHASE-I TRIAL OF PACLITAXEL AND GEMCITABINE ADMINISTERED EVERY 2 WEEKS IN PATIENTS WITH REFRACTORY SOLID TUMORS, Annals of oncology, 9(7), 1998, pp. 733-738
PROLONGED ADMINISTRATION OF BAY-12-9566, AN ORAL NONPEPTIDIC BIPHENYLMATRIX - A PHASE-I AND PHARMACOLOGICAL STUDY
Authors: ROWINSKY E HAMMOND L AYLESWORTH C HUMPHREY R SMETZER L SIU L WEISS G SMITH L THURMAN A RODRIGUEZ G SORENSEN M VONHOFF D ECKHARDT SG
Citation: E. Rowinsky et al., PROLONGED ADMINISTRATION OF BAY-12-9566, AN ORAL NONPEPTIDIC BIPHENYLMATRIX - A PHASE-I AND PHARMACOLOGICAL STUDY, Annals of oncology, 9, 1998, pp. 287-287
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF DOCETAXEL IN CANCER-PATIENTS WITH LIVER DYSFUNCTION DUE TO MALIGNANCIES
Authors: BAKER SD RAVDIN P AYLESWORTH C SMETZER L BRUNO R VERNILLET L PAZDUR R DOYLE G HAMMERSHAIMB L HOOKER E BURRIS HA ECKHARDT SG JOHNSON T KRAYNAK M HAMMOND L RODRIGUEZ G WEISS G ROWINSKY EK
Citation: Sd. Baker et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF DOCETAXEL IN CANCER-PATIENTS WITH LIVER DYSFUNCTION DUE TO MALIGNANCIES, Annals of oncology, 9, 1998, pp. 388-388
PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE DIARYLSULFONYLUREA LY295501 ADMINISTERED AS A SINGLE ORAL DOSE WEEKLY FOR 3 WEEKS EVERY 4 WEEKS
Authors: DIAB S BAKER SD HAMMOND L VILLALONA M ECKHARDT SG TINU C WEISS G KRAYNAK M AYLESWORTH C SMITH L RODRIGUEZ G DRENGLER R PATIL R SIU L ROTHENBERG M SMETZER L NYHART E STORNIOLO AM VONHOFF D ROWINSKY E
Citation: S. Diab et al., PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE DIARYLSULFONYLUREA LY295501 ADMINISTERED AS A SINGLE ORAL DOSE WEEKLY FOR 3 WEEKS EVERY 4 WEEKS, Annals of oncology, 9, 1998, pp. 440-440
DOSE-ESCALATION USING THE MODIFIED CONTINUAL REASSESSMENT METHOD (MCRM) IN PHASE-I CLINICAL-TRIALS - A REVIEW OF THE SAN-ANTONIO EXPERIENCE
Authors: SIU LL ROWINSKY EK CLARK GM DEMOOR C AYLESWORTH C VONHOFF DD ECKHARDT SG
Citation: Ll. Siu et al., DOSE-ESCALATION USING THE MODIFIED CONTINUAL REASSESSMENT METHOD (MCRM) IN PHASE-I CLINICAL-TRIALS - A REVIEW OF THE SAN-ANTONIO EXPERIENCE, Annals of oncology, 9, 1998, pp. 487-487
A PHASE-I SAFETY AND PHARMACOKINETIC (PK) STUDY OF BCH-4556, A NOVEL L-NUCLEOSIDE ANTIMETABOLITE, ON A DAILY X 5 DAY EVERY 21-DAY SCHEDULE IN PATIENTS WITH SOLID NEOPLASMS
Authors: STEPHENSON J BAKER SD AYLESWORTH C SIU L SIMMONS C SHARMA S SMITH L PROULX L MARSOLAIS C HUNT W VONHOFF D ROWINSKY E
Citation: J. Stephenson et al., A PHASE-I SAFETY AND PHARMACOKINETIC (PK) STUDY OF BCH-4556, A NOVEL L-NUCLEOSIDE ANTIMETABOLITE, ON A DAILY X 5 DAY EVERY 21-DAY SCHEDULE IN PATIENTS WITH SOLID NEOPLASMS, Annals of oncology, 9, 1998, pp. 596-596
PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE GLYCINAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE INHIBITOR LY309887 AS A BOLUS EVERY 3 WEEKS WITHFOLIC-ACID
Authors: AYLESWORTH C BAKER SD STEPHENSON J BRITTEN C MONROE P WALLING J JOHNSON R VONHOFF D ROWINSKY E
Citation: C. Aylesworth et al., PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE GLYCINAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE INHIBITOR LY309887 AS A BOLUS EVERY 3 WEEKS WITHFOLIC-ACID, Annals of oncology, 9, 1998, pp. 610-610
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF ZD9331, A NOVEL LONG-ACTING THYMIDYLATE SYNTHETASE (TS) INHIBITOR, ON A SINGLE DOSING EVERY 3 WEEKS SCHEDULE
Authors: DIAB S BRITTEN C SMITH R ECKHARDT SG BAKER S HAMMOND L SIU L SHARMA S HIDALGO M AYLESWORTH C YOUNG R WONG L RAZVILLAS B KRAYNAK M DOUGLASS E VONHOFF D ROWINSKY E
Citation: S. Diab et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF ZD9331, A NOVEL LONG-ACTING THYMIDYLATE SYNTHETASE (TS) INHIBITOR, ON A SINGLE DOSING EVERY 3 WEEKS SCHEDULE, Annals of oncology, 9, 1998, pp. 611-611
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE MULTITARGETED ANTIFOL(MTA) LY231514 WITH FOLIC-ACID (FA)
Authors: HAMMOND L BAKER SD VILLALONACALERO M ECKHARDT SG DRENGLER R AYLESWORTH C JOHNSON T HIDALGO M RODRIGUEZ G DIAB S MONROE P THORNTON D JOHNSON R VONHOFF D ROWINSKY E
Citation: L. Hammond et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE MULTITARGETED ANTIFOL(MTA) LY231514 WITH FOLIC-ACID (FA), Annals of oncology, 9, 1998, pp. 612-612
A PHASE-I DOSE-ESCALATION STUDY OF THE MULTITARGETED ANTIFOLATE, LY231514 (MTA) IN COMBINATION WITH 5-FLUOROURACIL (5-FU) - DEPENDENCE OF TOXICITY ON SCHEDULE OF 5-FU ADMINISTRATION
Authors: JOHNSON T SCHWARTZ G MCCUNE D STEPHENSON J AYLESWORTH C HAMMOND L MONROE P THORNTON D VONHOFF D ROWINSKY E
Citation: T. Johnson et al., A PHASE-I DOSE-ESCALATION STUDY OF THE MULTITARGETED ANTIFOLATE, LY231514 (MTA) IN COMBINATION WITH 5-FLUOROURACIL (5-FU) - DEPENDENCE OF TOXICITY ON SCHEDULE OF 5-FU ADMINISTRATION, Annals of oncology, 9, 1998, pp. 613-613
PHASE-I AND PHARMACOKINETIC STUDY OF PACLITAXEL IN COMBINATION WITH BIRICODAR, A NOVEL AGENT THAT REVERSES MULTIDRUG-RESISTANCE CONFERRED BY OVEREXPRESSION OF BOTH MDR1 AND MRP
Authors: ROWINSKY EK SMITH L WANG YM CHATURVEDI P VILLALONA M CAMPBELL E AYLESWORTH C ECKHARDT SG HAMMOND L KRAYNAK M DRENGLER R STEPHENSON J HARDING MW VONHOFF DD
Citation: Ek. Rowinsky et al., PHASE-I AND PHARMACOKINETIC STUDY OF PACLITAXEL IN COMBINATION WITH BIRICODAR, A NOVEL AGENT THAT REVERSES MULTIDRUG-RESISTANCE CONFERRED BY OVEREXPRESSION OF BOTH MDR1 AND MRP, Journal of clinical oncology, 16(9), 1998, pp. 2964-2976
PHASE-I AND PHARMACOKINETIC STUDY OF THE WATER-SOLUBLE DOLASTATIN-15 ANALOG LU103793 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
Authors: VILLALONACALERO MA BAKER SD HAMMOND L AYLESWORTH C ECKHARDT SG KRAYNAK M FRAM R FISCHKOFF S VELAGAPUDI R TOPPMEYER D RAZVILLAS B JAKIMOWICZ K VANHOFF DD ROWINSKY E
Citation: Ma. Villalonacalero et al., PHASE-I AND PHARMACOKINETIC STUDY OF THE WATER-SOLUBLE DOLASTATIN-15 ANALOG LU103793 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES, Journal of clinical oncology, 16(8), 1998, pp. 2770-2779
EXTRAMEDULLARY MYELOID CELL TUMORS IN MYELODYSPLASTIC-SYNDROMES - NOTA TRUE INDICATION OF IMPENDING ACUTE MYELOID-LEUKEMIA
Authors: BYRD JC EDENFIELD WJ DOW NS AYLESWORTH C DAWSON N
Citation: Jc. Byrd et al., EXTRAMEDULLARY MYELOID CELL TUMORS IN MYELODYSPLASTIC-SYNDROMES - NOTA TRUE INDICATION OF IMPENDING ACUTE MYELOID-LEUKEMIA, Leukemia & lymphoma, 21(1-2), 1996, pp. 153-159
EXTRAMEDULLARY LEUKEMIA (EML) IN MYELODYSPLASTIC SYNDROMES (MDS) - NOT A TRUE INDICATION OF IMPENDING ACUTE MYELOID-LEUKEMIA (AML)
Authors: EDENFIELD WJ BYRD JC AYLESWORTH C DOW NS DAWSON N
Citation: Wj. Edenfield et al., EXTRAMEDULLARY LEUKEMIA (EML) IN MYELODYSPLASTIC SYNDROMES (MDS) - NOT A TRUE INDICATION OF IMPENDING ACUTE MYELOID-LEUKEMIA (AML), Blood, 84(10), 1994, pp. 10000631-10000631
Risultati: 1-14 |